Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A1 | P68400 | 6/20 | 0.43 |
| ▸ | CSNK2A2 | P19784 | 2/20 | 0.43 |
| ▸ | CSNK2B | P67870 | 2/20 | 0.43 |
| ▸ | RXRA | P19793 | 1/20 | 0.40 |
| ▸ | RXRB | P28702 | 1/20 | 0.40 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.39 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.38 |
| ▸ | MAP4K4 | O95819 | 4/20 | 0.37 |
| ▸ | NEK2 | P51955 | 1/20 | 0.37 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.36 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.36 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.36 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.35 |
| ▸ | AURKA | O14965 | 1/20 | 0.35 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.35 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5582010 | 0.94 | CSNK2A2 (0.47) | CSNK2A1CSNK2A2CSNK2BLRRK2TBK1 | |
| SCHEMBL5581713 | 0.92 | CSNK2A1 (0.42) | CSNK2A1CSNK2A2CSNK2BLRRK2TBK1 | |
| SCHEMBL5582212 | 0.92 | CSNK2A1 (0.49) | CSNK2A1CSNK2A2CSNK2BLRRK2MAP4K4 | |
| SCHEMBL5582330 | 0.90 | CSNK2A1 (0.48) | CSNK2A1CSNK2A2CSNK2BTBK1MAP4K4 | |
| SCHEMBL5582325 | 0.89 | KMO (0.43) | CSNK2A1CSNK2A2CSNK2BLRRK2TBK1 | |
| SCHEMBL5582013 | 0.89 | CSNK2A1 (0.51) | CSNK2A1CSNK2A2CSNK2BLRRK2 | |
| SCHEMBL5582036 | 0.88 | PTPN11 (0.43) | CSNK2A1CSNK2A2CSNK2BLRRK2TBK1 | |
| SCHEMBL5582267 | 0.88 | CSNK2A1 (0.46) | CSNK2A1CSNK2A2CSNK2BLRRK2MAP4K4 | |
| SCHEMBL5581859 | 0.87 | MAP4K4 (0.47) | CSNK2A1CSNK2A2CSNK2BLRRK2MAP4K4 | |
| SCHEMBL5582062 | 0.85 | MKNK1 (0.44) | CSNK2A1CSNK2A2CSNK2BPTK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070225308-A1 | 2-Amino Quinazoline Derivative | KYOWA HAKKO KOGYO CO.,LTD. (JP) | 2007-09-27 | — | — | US | disclosed |
| EP-1726584-A1 | 2-AMINOQUINAZOLINE DERIVATIVE | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2006-11-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225308-A1 | 2-Amino Quinazoline Derivative | AGTR2, ABL1, AGTR1 | CSNK2A1 602/4885CSNK2A2 467/4885CSNK2B 662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.